CBD Life Sciences Inc. (CBDL)
OTC PINK OTC PINK Primary 
CBD Life Sciences Inc. (CBDL) in Final Stages to Sell CBD Products on DoorDash Platform
With DoorDash projecting over $10 billion in 2025 revenue, CBD Life Sciences Inc. is set to tap into one of the fastest-growing delivery markets in the country, potentially unlocking a multi-million dollar revenue stream and driving a projected 30-40% increase in annual revenue for CBDL. SCOTTSDALE, ARIZONA / ACCESSWIRE / January 14, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD industry, proudly announces that it is in the final stages of securing approval to sell its premium CBD products on DoorDash, one of the most prominent on-demand delivery platforms in the United States.
CBD Life Sciences, Inc. (CBDL) Secures Breakthrough Walmart Marketplace Approval for Mushroom Supplement, Setting the Stage for Unprecedented Growth
Walmart Marketplace saw a 60% year-over-year growth in gross merchandise volume, with third-party sellers accounting for over 50% of online sales, contributing to Walmart's e-commerce revenue surpassing $100 billion in 2024. This makes it a powerful platform for rapid brand growth and a game-changing opportunity for CBDL's breakthrough product line.
CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization
Demonstrating shareholder confidence, CBDL commits to repurchasing 10% of revenue quarterly. SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value.
CBD Life Sciences Inc. (CBDL) Looking to Acquire a Cannabis Growth License in North Las Vegas
Target Acquisition Valued at $10 Million with Projected 2025 Gross Revenue of $5 Million, Positioning CBDL for Explosive Growth in Nevada's Burgeoning Cannabis Market SCOTTSDALE, AZ / ACCESSWIRE / December 11, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a leader in CBD innovation, announces its intent to acquire a cannabis growth license in North Las Vegas, a move that could serve as a transformative step in the company's evolution. With a target business value of $10 million and a projected $5 million in gross revenue by 2025, this acquisition positions CBDL at the forefront of Nevada's thriving cannabis cultivation market, which is projected to surpass $1.3 billion by 2025.
CBD Life Sciences, Inc. (CBDL) Reports Stunning 622% Revenue Growth From June to November 2024
Exploding with momentum: CBDL shatters records with 622% revenue growth in five months, propelling to a 1,405% year-to-date increase-a game-changer in the CBD industry. SCOTTSDALE, ARIZONA / ACCESSWIRE / December 5, 2024 / CBD Life Sciences, Inc. (CBDL), a leading innovator in the CBD industry, is proud to announce an extraordinary 622% increase in revenue over the five-month period from June to November 2024.
CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary
With the New York cannabis market projected to surpass $5 billion by 2027, this acquisition positions CBDL for exponential revenue growth and expanded market dominance. SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneering force in the CBD and cannabis industries, is proud to announce the signing of a pivotal Letter of Intent (LOI) to acquire an interest in a cannabis dispensary located in New York.
CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
CBD Life Sciences, Inc. (CBDL) Positioned for Unmatched Growth as Trump Welcomes Weed Legalization and Federal Rescheduling
The global cannabis market size was valued at USD 43.72 billion in 2022 and is projected to grow from USD 57.18 billion in 2023 to USD 444.34 billion by 2030, exhibiting a CAGR of 34.03% during the forecast period. North America dominated the global market with a share of 81.79% in 2022.
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High-Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value
The global CBD pet care market, which includes products for animals like dogs, cats, and horses, was valued at approximately $125 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 40.3% from 2021 to 2028. SCOTTSDALE, AZ / ACCESSWIRE / October 29, 2024 / CBD Life Sciences Inc. (CBDL), an innovative leader in the CBD industry, is positioning itself to capitalize on the rapidly expanding CBD pet care market with a bold entry into equine products.
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push
With the potential for explosive profits in a $70 billion industry, CBDL's innovative product line and strategic market positioning stand ready to deliver unparalleled returns for shareholders, making this a true game changer in the Hemp market. SCOTTSDALE, AZ / ACCESSWIRE / October 24, 2024 / The U.S. is on the verge of a historic shift.
CBD Life Sciences, Inc. (CBDL) Announces a Staggering 1744.00% Revenue Growth as Innovation and Strategic Expansion Drive Market Dominance
As the global CBD market is projected to reach $47 billion by 2028, CBDL's groundbreaking product innovations, retail expansion, and strategic partnerships position the company for unparalleled growth and industry leadership. SCOTTSDALE, AZ / ACCESSWIRE / October 17, 2024 / CBD Life Sciences, Inc. (CBDL), a trailblazer in the rapidly expanding CBD and wellness industry, proudly announces a remarkable 1744.00% increase in revenue since February 2024.
CBD Life Sciences, Inc. (CBDL) Announces Strategic MOU With U.S. Armed Forces for Groundbreaking Mushroom Supplement
CBD Life Sciences propels its expansion with a major MOU, positioning the company for multi-million-dollar growth in the booming $14.6 billion adaptogens market. SCOTTSDALE, AZ / ACCESSWIRE / October 15, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL) is excited to announce the signing of a game-changing Memorandum of Understanding (MOU) with a division of the United States Armed Forces, marking a pivotal moment in the company's journey toward revolutionizing health and performance solutions.
